CAMBRIDGE, Mass. – UConn lost a hard-fought battle to Harvard with a final score of 1-0 in the second round of the NCAA Tournament this afternoon.
The Huskies opened strong defensively, denying Harvard’s lone penalty corner of the…

CAMBRIDGE, Mass. – UConn lost a hard-fought battle to Harvard with a final score of 1-0 in the second round of the NCAA Tournament this afternoon.
The Huskies opened strong defensively, denying Harvard’s lone penalty corner of the…

When the solar system formed about 4.6 billion years ago, a gigantic cloud of dust and gas collapsed on itself. And according to a recent study, without Jupiter’s help, Earth would have been swallowed up by the sun.
It must be said that the

By Claudia Assis
Chevron and Exxon are ‘deep-pocketed names that are thinking 20 and 30 years out’
Chevron plans to boost oil and gas production by up to 3% a year through 2030. Exxon’s five-year plan calls for an output increase of about 18%.
Chevron Corp. and Exxon Mobil Corp. plan to boost their oil and gas production over the next five years, even as falling oil prices may leave investors scratching their heads at the companies’ moves.
Chevron (CVX) and Exxon (XOM) are energy giants that look at longer cycles – and they have a wealth of experience playing the long game. They both benefit from their size and footprint and are among the few remaining global integrated energy companies, meaning they also refine crude oil and have robust chemicals businesses.
“They have a long-term horizon, and a lot of their projects are long-term in nature too,” said Simon Wong, a portfolio manager with Gabelli Funds. The refining side of their business has fared well this year, and they have also made acquisitions recently that contributed to that higher production, he said.
To understand the increases in production amid weakening prices for crude futures, it helps to think in terms of the companies’ long and short cycles, said Stewart Glickman, an analyst at CFRA Research.
Longer cycles are easier to understand, Glickman said. Those carry a bigger price tag and take years to mature, and their development continues through short-term market weakness. Chevron and Exxon are “deep-pocketed names that are thinking 20 and 30 years out,” he said.
Shorter-cycle projects are usually land-based, where costs are lower, and they are easier to stop and start. Both Chevron and Exxon are expanding in one such area, the Permian Basin in West Texas, and it’s possible that both feel they have advantages over smaller peers that “will result in their taking market share, while the weaker hands get shaken out of the market,” Glickman said.
Exxon’s deal for Pioneer Natural Resources Co., announced in 2023, made the oil giant’s North America holdings even more attractive for a relatively modest price.
Chevron’s acquisition of Hess Corp., completed earlier this year after a tug-of-war with Exxon over assets in Guyana, addressed investors’ concerns about the quality and longevity of Chevron’s international portfolio.
At this week’s investor day, Chevron said it plans to boost oil and gas production by up to 3% a year through 2030. Exxon’s five-year plan, announced last December, calls for an increase in output of about 18%.
Chevron’s investor update seemed to highlight the company’s attractiveness to a broader swath of investors, which hasn’t been easy to accomplish with the energy sector underperforming the broader equity market. The Energy Select Sector SPDR exchange-traded fund XLE is up about 7% this year, while the S&P 500 index SPX is up about twice as much in the same period.
One of the key factors keeping the “elusive generalist investor” from investing in energy stocks has been the risk of a downside in oil prices, J.P. Morgan analyst Arun Jayaram wrote in a note this week. At its investor day, Chevron did an effective job of highlighting the resilience of the portfolio amid those lower prices, Jayaram said.
Crude-oil futures in New York (CL.1) are down around 18% this year, and London-based ICE Brent crude prices (BRN00) are off about 14% over the same period. Wall Street is generally cautious on energy and energy prices, with the view that major oil-producing countries could continue to allow crude prices to drift lower.
The Organization of the Petroleum Exporting Countries and its allies, known as OPEC+, had been announcing monthly oil-production increases since April. Earlier this month, the group said it would pause the hikes in the first quarter of 2026, following a modest increase in December. The first quarter of the year usually shows weaker demand for oil.
A recent global energy-demand forecast called for growing consumption of oil and gas. The International Energy Agency said consumption will increase through 2050, as adoption of electric vehicles missed earlier estimates.
When comparing the two energy giants, Chevron usually has an edge over Exxon on Wall Street.
“I like both of them equally, but if I had to choose one, at this point I’d say Chevron,” Gabelli Funds’ Wong said. “But both of them are very well-run companies.”
In the last three or four years, Chevron has spent a lot on projects, but it is now holding on to more of its cash to give back to shareholders, he said.
Wall Street rates the shares of both companies highly. Of 29 analysts polled by FactSet covering Chevron, 15 rate the stock a buy and 13 give it a hold rating. Of 30 analysts on Exxon, 14 rate the stock a buy and 15 give it a hold rating. Chevron and Exxon shares each have one sell rating, according to FactSet.
-Claudia Assis
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-16-25 1510ET
Copyright (c) 2025 Dow Jones & Company, Inc.



The Australian market is experiencing turbulence, with the ASX 200 futures indicating a significant drop following the recent end of the U.S. government shutdown and ongoing economic uncertainties. Despite this volatility, penny stocks continue to capture investor interest due to their affordability and potential for growth. While often associated with smaller or newer companies, these stocks can offer intriguing opportunities when backed by strong financials and strategic positioning. In this article, we’ll explore three noteworthy penny stocks on the ASX that stand out for their potential resilience and growth prospects amidst current market conditions.
|
Name |
Share Price |
Market Cap |
Financial Health Rating |
|
Alfabs Australia (ASX:AAL) |
A$0.45 |
A$128.96M |
★★★★★☆ |
|
Dusk Group (ASX:DSK) |
A$0.84 |
A$52.31M |
★★★★★★ |
|
IVE Group (ASX:IGL) |
A$3.01 |
A$462.61M |
★★★★★☆ |
|
MotorCycle Holdings (ASX:MTO) |
A$3.73 |
A$275.3M |
★★★★★★ |
|
West African Resources (ASX:WAF) |
A$3.04 |
A$3.47B |
★★★★★★ |
|
LaserBond (ASX:LBL) |
A$0.50 |
A$59.04M |
★★★★★★ |
|
Bravura Solutions (ASX:BVS) |
A$2.31 |
A$1.04B |
★★★★★★ |
|
Praemium (ASX:PPS) |
A$0.81 |
A$387.52M |
★★★★★★ |
|
Service Stream (ASX:SSM) |
A$2.25 |
A$1.38B |
★★★★★★ |
|
GWA Group (ASX:GWA) |
A$2.38 |
A$624.51M |
★★★★★☆ |
Click here to see the full list of 414 stocks from our ASX Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Immutep Limited is a biotechnology company focused on developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia, with a market cap of A$404.78 million.
Operations: Immutep generates revenue primarily from its immunotherapy segment, which accounts for A$5.03 million.
Market Cap: A$404.78M
Immutep Limited, a biotechnology company with a market cap of A$404.78 million, is currently pre-revenue and unprofitable, reporting A$5.03 million in revenue from its immunotherapy segment. Despite this, the company has made significant strides in clinical trials for its novel LAG-3 related immunotherapies like eftilagimod alfa (efti), which has shown promising results in treating various cancers including non-small cell lung cancer and soft tissue sarcoma. Recent positive trial data and FDA Fast Track designations highlight potential future growth avenues. Immutep’s financial stability is bolstered by sufficient cash reserves exceeding its liabilities.

New Zealand’s Daryl Mitchell bats during the first one-day international cricket match between New Zealand and West Indies at Hagley Oval in Christchurch on November 16, 2025.
| Photo…

Renowned computer scientist Yoshua Bengio has made history by becoming the first living researcher to surpass one million citations on Google Scholar, a milestone almost unheard of in modern academia. The achievement reflects not only…

FRISCO, Texas – A Frisco woman has been sentenced to eight years in federal prison for making false statements related to international terrorism, Acting U.S. Attorney Jay R. Combs announced.
Kahkashan Haider Khan, 54, a U.S….

Meditation app Headspace is bringing back one of its biggest annual deals this Black Friday. Through December 4, you’ll be able to get 50 percent off the regular annual subscription price, bringing a full year of guided meditations, sleep…